| DC74620 |
OATD-02 |
OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study. |
|
| DC74621 |
Icalcaprant |
Icalcaprant is a kappa-opioid receptor antagonist. |
|
| DC74622 |
Igermetostat |
Igermetostat is EZH2 inhibitor, used in cancer research in vivo and in vitro. |
|
| DC74623 |
SPC-180002 |
SPC-180002 is a SIRT1/3 dual inhibitor, with IC50 values of 1.13 and 5.41 μM, respectively. SPC-180002 disturbs redox homeostasis via ROS generation, which leads to an increase in both p21 protein stability and mitochondrial dysfunction. SPC-180002 strongly inhibits cell cycle progression and cancer cell growth. SPC-180002 activates the Nrf2 signaling pathway. |
|
| DC74624 |
Tibremciclib |
Tibremciclib is a CDK4 inhibitor with antineoplastic activity. |
|
| DC74625 |
Votoplam |
Votoplam is a gene splicing modulator, used to inhibit Huntington's disease. |
|
| DC74626 |
Lacutoclax |
Lacutoclax is a Bcl-2 inhibitor with antineoplastic activity. |
|
| DC74627 |
NSC89641 |
NSC89641 inhibits MERS-CoV Mpro, with an IC50 value < 3.5 μM. NSC89641 exhibits the high inhibitory potency against SARS-CoV-2 Mpro enzymatic activity, with an IC50 of 3.05 μM. |
|
| DC74628 |
PC-766B |
PC-766B is a macrolide antibiotic. PC-766B is active against Gram-positive bacteria, and some fungi and yeasts, but inactive against Gram-negative bacteria. PC-766B shows antitumor activity against murine tumor cells. PC-766B has weak inhibitory activity against Na+, K+-ATPase. |
|
| DC74629 |
Zevotrelvir |
Zevotrelvir (Compound 52) is a coronavirus inhibitor with IC50 ranges of <0.1 μM and <0.1mM for 229E hCoV and SARS-CoV-23C-like (3CL) proteases, respectively. Zevotrelvir has the potential to study viral infections. |
|
| DC65960 |
canthin-6-one-9-O-β-D-glucopyranoside
Featured
|
|
|
| DC65961 |
10-methy1-6-one
Featured
|
|
|
| DC65962 |
10-B-D-glucopyranosyloxycanthin-6-one
Featured
|
|
|
| DC60560 |
HRX215
Featured
|
HRX215 is a first-in-class MKK4 inhibitor with IC50 of 0.02 μM and shows above 100-fold selectivity against JNK1, BRAF, and MKK7. HRX215 increases liver regeneration after hepatectomy in murine and porcine models. |
|
| DC60562 |
KSQ-4279 (Synonyms: USP1-IN-1)
Featured
|
KSQ-4279 is a USP1 and PARP inhibitor. KSQ-4279 showed anti-proliferative effects in a subset of cell lines, often characterized by the presence of homologous recombination deficiencies (HRD), including mutations in BRCA1/2. The combination of KSQ-4279 with olaparib was able to induce strong and durable regressions across a number of ovarian and TNBC PDX models. |
|
| DC90056 |
PLX-5622 HCl form (water solubility form)
Featured
|
PLX5622 is the HCl salt form of PLX-5622, which has better water solubility.PLX-5622 is a highly selective brain-penetrant CSF1R inhibitor (IC50=0.016 µM; Ki=5.9 nM) allowing for extended and specific microglial elimination, preceding and during pathology development. |
|
| DC60563 |
6-Diazo-5-oxo-L-nor-Leucine
Featured
|
6-Diazo-5-oxo-L-nor-Leucine (DON) is a glutamine analog that inhibits glutaminases (Ki = 6 µM) and other glutamine-utilizing enzymes, including cytidine triphosphate synthase (CTPS), which uses glutamine in the synthesis of CTP.1,2,3 DON is commonly used in cells or tissues but its use in whole animals is limited by its teratogenicity. |
|
| DC60564 |
Lipid GVS-18-B6
Featured
|
Lipid GVS-18-B6 is a silicon ether ionizable lipid for mRNA delivery. GVS-18-B6 showes particularly good liver specificity, with a liver-to-spleen EGFP signal ratio of 92:1. GVS-18-B6 also showes rapid tissue clearance within 6 hours of dosing. |
|
| DC60565 |
RMC-7977
Featured
|
RMC-7977 is a reversible, tri-complex RAS inhibitor with broad spectrum activity for both mutant and wild-type (WT) KRAS, NRAS, and HRAS variants.RMC-7977 can lead to tumor regressions and was well tolerated in diverse RAS-addicted preclinical cancer models. RMC-7977 also can inhibit the growth of KRASG12C cancer models. |
|
| DC60566 |
Lipid CAD9 (3-A2-7b)
Featured
|
Lipid CAD9 (3-A2-7b is a cationic degradable (CAD) lipid. 3-A2-7b formulated LNP, LNP-CAD9, can deliver FLuc mRNA to the lungs in vivo. LNP-CAD9 co-delivering Cas9 mRNA/VEGFR2 single guide RNA (sgRNA) effectively induces VEGFR2 knock out in lung endothelial cells of female mice. |
|
| DC60567 |
dCeMM1
Featured
|
dCeMM1 is a RBM39 glue degrader. dCeMM1 shows functions by re-directing the activity of the CRL4DCAF15 ligase. dCeMM1 decreases the expression of RBM39 levels in WT KBM7 cells[1]. |
|
| DC65963 |
Acid-PEG5-C2-Boc
Featured
|
AAcid-PEG5-C2-Boc is a PEG derivative containing a t-butyl protected carboxyl group with a terminal carboxylic acid. The terminal carboxylic acid can be reacted with primary amine groups in the presence of activators (e.g. EDC, or DCC) to form a stable amide bond. The hydrophilic PEG spacer increases solubility in aqueous media. The t-butyl protected carboxyl group can be deprotected under acidic conditions. |
|
| DC65964 |
tert-Butyl 5-Hydroxypentanoate
Featured
|
|
|
| DC65965 |
Tri-GalNAc(OAc)3
Featured
|
Tri-GalNAc(OAc)3 is a triantenerrary N-acetylgalactosamine (tri-GalNAc) with an amino group, which is useful precursor for synthesis of GalNAc-LYTAC that engage the asialoglycoprotein receptor for targeted protein degradation. Tri-GalNAc(OAc)3 was first reported in Nat Chem Biol. 2021 Sep;17(9):937-946 (compound ). This product has no formal name at the moment. |
|
| DC65966 |
DSPE-PEG2000-triGalNAc ammonium
Featured
|
DSPE-PEG2K-triGalNAc is a polar lipid composed of DSPE and tri-N-acetylgalactosamine that can be used to construct liposomes target to asialoglycoprotein receptor (ASGPR). |
|
| DC60568 |
RMC-9805
Featured
|
RMC-9805 is a first-in-class, mutant-selective, covalent and orally bioavailable KRAS-G12D(ON) inhibitor. RMC-9805 exhibits direct anti-tumor effects and indirectly transformed the TME through inhibition of cancer cell-intrinsic KRAS-G12D oncogenic signaling. |
|
| DC60569 |
ABBV-303
Featured
|
ABBV-303 is a novel c-Met targeted multispecific NK cell engager. ABBV-303 binding to NKG2D and CD16a results in redirection of both innate (NK cells) and adaptive (CD8+ T cells) immune cells to lyse c-Met expressing tumor cells. |
|
| DC60570 |
ORIC-944
Featured
|
ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer. |
|
| DC60571 |
BBO-8520
Featured
|
BBO-8520 is a first-in-class, direct covalent inhibitor of both KRAS-G12C (ON) and (OFF) states. BBO-8520 displays highly significant binding to KRAS-G12C in a global cysteine proteome analysis and is 100x more selective for KRAS-G12C than for WT-KRAS and other mutant isoforms, with no measurable activity against N- or H-RAS. |
|
| DC60572 |
NST-628
Featured
|
NST-628 is a potent pan-RAF-MEK molecular glue that prevents phosphorylation and activation of MEK by RAF. NST-628 demonstrates broad efficacy in cellular and patient-derived, in vivo tumor models harboring KRAS, NRAS, BRAF class II/III, and NF1 mutations. |
|
